Overview

A Phase 1,Open-label Study of BPI-421286 in Subjects With Advanced Solid Tumors

Status:
Recruiting
Trial end date:
2023-07-31
Target enrollment:
0
Participant gender:
All
Summary
Evaluate the safety and tolerability of BPI-421286 in adult subjects with advanced solid tumors. Estimate the maximum tolerated dose (MTD) and/or a recommended phase 2 dose (RP2D) in adult subjects with advanced solid tumors.
Phase:
Phase 1
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Betta Pharmaceuticals Co., Ltd.
Criteria
Inclusion Criteria:

- Pathologically documented, locally-advanced or metastatic malignancy

- Standard treatment is not available or patient declines

- Adequate organ function

Exclusion Criteria:

- Active brain metastases from non-brain tumors.

- Gastrointestinal (GI) tract disease causing the inability to take oral medication.

- Other protocol specified criteria